There’s a certain kind of exhaustion that comes with living with paroxysmal nocturnal hemoglobinuria (PNH) that isn’t just physical. It’s emotional, mental, and sometimes even spiritual. Recently, I found myself back in that space after experiencing a flare-up with symptoms that reminded me just how unpredictable this disease…
Fabhalta (iptacopan) appears to outperform Empaveli (pegcetacoplan) in raising hemoglobin levels and reducing the need for blood transfusions in adults with paroxysmal nocturnal hemoglobinuria (PNH) who continue to have symptoms despite previous treatment. Those are the findings of a new study that indirectly compared the two approved…
Biogen has entered into an agreement to acquire Apellis Pharmaceuticals, adding Empaveli (pegcetacoplan), marketed in Europe as Aspaveli, to its portfolio for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and two other rare diseases involving abnormal complement activation, which is part of the immune system. For Biogen,…
Discussion
One of the hardest lessons that comes with living with paroxysmal nocturnal hemoglobinuria (PNH) is learning that control doesn’t always look the way you thought it would. Before a PNH diagnosis, control can feel straightforward. You plan your days, set your goals, and expect your body to cooperate.
Get regular updates delivered to your inbox.
